Literature DB >> 31744887

Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer.

Mustafa Zelal Muallem1, Jalid Sehouli2, Rolf Richter2, Aygun Babayeva3, Khayal Gasimli3, Asya Parashkevova3.   

Abstract

OBJECTIVE: Prediction of post-operative residual disease after ovarian cancer cytoreductive surgery remains a topic of interest to gynecologic oncologists. The aim of this study was to explore the correlation between serum CA125, peritoneal cancer index, and intra-operative mapping of ovarian cancer and their predictive value for post-operative outcome.
METHODS: A total of 70 patients with primary epithelial ovarian cancer, who underwent primary cytoreductive surgery at Charité, Berlin between January 2013 and February 2014 were included. In all patients, pre-operative CA125 values, intra-operative peritoneal cancer index, and intra-operative mapping of ovarian cancer were determined.
RESULTS: Using a receiver operating characteristic analysis, cut-off values for CA125, peritoneal cancer index, and intra-operative mapping of ovarian cancer score could be defined. Patients with pre-operative serum CA125 >600 U/mL had a three times higher risk for residual tumor after primary cytoreductive surgery (p=0.037). A peritoneal cancer index score >20 indicated a nine times increased risk for residual tumor (p=0.003). More than six affected abdominopelvic fields on the intra-operative mapping of ovarian cancer was associated with a 25 times higher risk of residual tumor after primary cytoreductive surgery (p≤0.05). The combination of all three values predicted residual tumor in up to 90% of patients.
CONCLUSION: We found that pre-operative CA125 >600 U/mL, peritoneal cancer index >20, and intra-operative mapping of ovarian cancer score >6 could be used as predictors of complete tumor resection. The combination of all these three values predicted the incomplete resection of disease in up to 90% of patients even in experienced centers. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cystadenocarcinoma; operative; peritoneal neoplasms; serous; surgical procedures

Mesh:

Substances:

Year:  2019        PMID: 31744887     DOI: 10.1136/ijgc-2019-000778

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [18F]FDG PET/CT volumetric parameters and tumour markers HE4 and CA125.

Authors:  Ariel Glickman; Pilar Paredes; Núria Carreras-Diéguez; Aida Niñerola-Baizán; Lydia Gaba; Jaume Pahisa; Pere Fusté; Marta Del Pino; Berta Díaz-Feijóo; Eduardo González-Bosquet; Núria Agustí; Nuria Sánchez-Izquierdo; David Fuster; Andrés Perissinotti; Inmaculada Romero; Esther Fernández-Galán; Josep Lluís Carrasco; Blanca Gil-Ibáñez; Aureli Torné
Journal:  Eur Radiol       Date:  2021-09-29       Impact factor: 7.034

Review 2.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

3.  Surgical treatment and fertility perservation in endometrial cancer.

Authors:  Nina Kovacevic
Journal:  Radiol Oncol       Date:  2021-02-11       Impact factor: 2.991

4.  Small Bowel PCI Score as a Prognostic Factor of Ovarian Cancer Patients Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a Retrospective Analysis of 130 Patients.

Authors:  Christos Iavazzo; Alexandros Fotiou; Victoria Psomiadou; Sofia Lekka; Dimitrios Katsanos; John Spiliotis
Journal:  Indian J Surg Oncol       Date:  2021-03-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.